Nasal Drug Delivery Market Growth & Forecast 2025: Industry Size, Share & Insights

The global nasal drug delivery market was valued at USD 42.39 billion in 2018 and is expected to grow to USD 120.83 billion by 2032, reflecting a CAGR of 7.9% over the forecast period. In 2018, Europe led the market, accounting for 49.82% of the global share.

Nasal drug delivery has emerged as a key focus area in pharmaceutical research, leading to the development of compact, user-friendly devices using advanced technologies. The nasal route is preferred for its rapid drug absorption and faster onset of action. Recently, companies have been exploring biotherapeutics, including polypeptides, peptides, and antisense DNA, as alternatives to injectable administration. These advancements are expected to drive market growth.

Market Segmentation:

Dry Powder Inhalers (DPIs) to Dominate the Market

The nasal drug delivery market is segmented into DPIs, MDIs, and nebulizers, with DPIs holding the largest share due to their stability, flexible dosing, and low susceptibility to microorganisms. MDIs rank second but pose challenges in proper usage due to complex steps, leading to frequent errors. Nebulizers hold a smaller share as they are mainly used in hospitals. Increasing efforts to develop user-friendly DPIs, such as Verona Pharma’s 2019 clinical trial success, are expected to drive market growth.

COPD to Lead in Application Segment

COPD holds the largest market share, with 16 million Americans affected annually, according to the CDC. The growing patient base drives inhaler adoption. Asthma is projected to be the fastest-growing segment due to its rising prevalence in emerging countries.

Retail Pharmacies to Drive Distribution Growth

Retail pharmacies lead the market due to easy accessibility and increasing demand for inhalers. Hospital pharmacies follow, supported by rising asthma and COPD-related hospital admissions.

Get a Free Sample Research PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/nasal-drug-delivery-market-100415

Major Players Profiled in the Nasal Drug Delivery Market Report:

• Consort Medical plc.

• AptarGroup, Inc.

• Vectura Group plc

• 3M

• H&T Presspart Manufacturing Ltd.

• Nemera

• GOFIRE INC.

• Teva Pharmaceutical Industries Ltd.

• Others

Market Drivers:

The rising prevalence of pulmonary diseases is driving demand for nasal drug delivery devices. WHO estimates 300 million people globally suffer from asthma, all relying on inhalation for effective treatment. Industry players are introducing patient-friendly, cost-effective devices, such as Aptar Pharma’s PureHale inhaler in 2018, to enhance respiratory care. COPD-related hospital admissions, particularly in Europe, are further fueling market growth, increasing demand for DPIs and MDIs. Additionally, the expiration of patents on branded inhalers is boosting the availability of generic alternatives, reducing treatment costs and increasing adoption. For instance, Mylan’s 2019 FDA-approved generic, Wixela Inhub, offers a lower-cost alternative to Advair Diskus. Growing awareness of these inhalers is expected to further drive market expansion.

Market Restraint:

Lack of Patient Awareness on Proper Dosage Administration May Hinder Market Growth

Despite the proven efficacy of DPIs and MDIs in delivering accurate doses, many patients struggle with proper usage, leading to ineffective treatment. A key challenge is the incorrect administration of these devices, particularly among older adults due to a lack of training and understanding. Improper use can result in under-dosing, negatively impacting patient health and limiting device adoption, which may slow market growth during the forecast period.

Regional Insights:

Our research indicates that Europe will hold the largest Nasal Drug Delivery market share during the forecast period, driven by the high prevalence of COPD and asthma. The region benefits from widespread awareness of inhaler advantages, with rising cases in Ireland and other developing European nations further fueling demand. Additionally, the growing acceptance of smart inhalers is expected to contribute to regional growth.

Meanwhile, Asia Pacific is projected to experience significant growth due to increasing inhaler adoption. Governments are actively promoting awareness campaigns, while biopharma companies are leveraging novel technologies to develop DPIs and MDIs. Substantial investments in smart inhalers, along with rising disease incidences and greater patient awareness, are expected to drive market expansion in the region.

Key Industry Developments:

• March 2021 – Aptar Pharma and its subsidiary, Noble, partnered with dne pharma, a leading addiction medicine company in Northern Europe. The collaboration focuses on providing nasal drug delivery expertise and training solutions for dne pharma’s Ventizolve nasal naloxone, used in opioid overdose treatment.

• February 2021 – Nanoform Finland and Herantis signed a non-exclusive agreement to collaborate on nasal drug delivery to the brain, aiming to develop formulation proof-of-concept projects.